Online citations, reference lists, and bibliographies.
← Back to Search

Surface-Functionalized Lipid Nanoparticles For Site-Specific Drug Delivery

D. Gaspar, A. Almeida
Published 2019 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Nanoparticles have been sought as drug carriers to increase bioavailability at the target site of action, improving drug therapeutic index. Among the several nanoparticulate systems proposed in the field of pharmaceutical technology, lipid-based nanoparticles (NPs) have attracted increasing attention due to their unique size-dependent properties, use of common well-tolerated, pharmaceutically accepted excipients, thus allowing for developing new delivery systems that could hold great promise for attaining the bioavailability enhancement along with controlled and site specific drug delivery. In the last years, passive and active modification approaches have been proposed to surface functionalization of lipid NPs intended for specific targeting. Internalizable ligands, specific targeted peptides, saccharide ligands, or even therapeutic molecules (e.g. antibodies or enzymes) are used for this purpose. Physicochemical properties of NPs can also be adjusted to improve drug targeting. The present chapter describes the recent advances in surface functionalization of lipid NPs, either solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), lipid–drug conjugate nanoparticles (LDC), or lipid nanocapsules (LNC) with specific ligands to enhance drug targeting performance as well as its therapeutic effect.
This paper references
10.1016/j.bbrc.2014.01.107
Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery.
T. Asai (2014)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.1146/annurev-bioeng-071811-150124
The effect of nanoparticle size, shape, and surface chemistry on biological systems.
Alexandre Albanese (2012)
10.1002/adhm.201600219
Design Advances in Particulate Systems for Biomedical Applications.
A. C. Lima (2016)
10.1021/acs.molpharmaceut.7b00169
Microencapsulated Solid Lipid Nanoparticles as a Hybrid Platform for Pulmonary Antibiotic Delivery.
D. Gaspar (2017)
10.1023/B:PHAM.0000045229.87844.21
Novel Long-Circulating Lipid Nanocapsules
D. Hoarau (2004)
10.1016/j.ijpharm.2013.06.037
Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity.
P. Blasi (2013)
10.1016/S1734-1140(12)70901-5
Nanoparticles as drug delivery systems.
A. Z. Wilczewska (2012)
10.1073/PNAS.0503879102
Mechanics of receptor-mediated endocytosis.
H. Gao (2005)
10.2147/IJN.S115136
Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
B. Liu (2017)
10.1021/nn500299p
Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency.
Edward A. Sykes (2014)
10.1016/j.nano.2012.10.003
Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells.
J. Madan (2013)
10.1007/s11051-015-3052-z
Permeation of platinum and rhodium nanoparticles through intact and damaged human skin
M. Mauro (2015)
10.1016/j.nano.2015.09.004
Nanostructured lipid carriers: Promising drug delivery systems for future clinics.
A. Beloqui (2016)
10.3109/10611860903115308
Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting
Navneet Nimje (2009)
10.3109/13880209.2013.876655
A promising targeted gene delivery system: Folate-modified dexamethasone-conjugated solid lipid nanoparticles
W. Wang (2014)
10.1016/j.jconrel.2016.08.006
NFL-lipid nanocapsules for brain neural stem cell targeting in vitro and in vivo.
D. Carradori (2016)
10.1016/J.EJPB.2005.02.006
Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN).
T. Göppert (2005)
10.1016/j.ejps.2017.12.006
Mannose‐functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages
A. Costa (2018)
10.1016/J.IJPHARM.2006.07.026
Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin.
N. Zhang (2006)
10.1038/srep18423
Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol
Cristiano Farace (2016)
10.1016/S0927-7765(02)00053-X
Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules
M. Garcia-Fuentes (2003)
10.1016/j.ejpb.2013.08.011
Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.
S. Martins (2013)
10.1602/neurorx.2.1.108
Drug transport to brain with targeted nanoparticles
J. Olivier (2011)
10.1016/j.jconrel.2017.11.015
Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer‐lipid hybrid nanoparticles
Tianyang Ren (2018)
10.1016/J.IJPHARM.2004.12.030
New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin.
M. Garcia-Fuentes (2005)
10.1098/rsta.2009.0273
Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles
R. A. Sperling (2010)
10.1016/j.imlet.2017.07.015
Nanoparticles and targeted drug delivery in cancer therapy.
B. Bahrami (2017)
10.1016/J.JTICE.2017.05.003
Using catanionic solid lipid nanoparticles with wheat germ agglutinin and lactoferrin for targeted delivery of etoposide to glioblastoma multiforme
Y. Kuo (2017)
10.3109/10611869609015973
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
R. Mueller (1996)
10.1016/0378-5173(95)04286-5
Crystallization tendency and polymorphic transitions in triglyceride nanoparticles
H. Bunjes (1996)
10.1016/j.colsurfb.2010.12.024
The size of solid lipid nanoparticles: an interpretation from experimental design.
Carla Vitorino (2011)
10.1016/j.ijpharm.2009.10.022
Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles.
L. B. Jensen (2010)
10.1007/s11051-015-2875-y
Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids
M. Durán‐Lobato (2015)
10.1016/j.addr.2012.04.010
Nanoparticles in drug delivery: past, present and future.
P. Couvreur (2013)
10.1016/j.ijpharm.2015.12.054
Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation.
Y. Kuo (2016)
10.1002/jps.23773
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.
J. C. Kraft (2014)
10.1016/j.jconrel.2017.07.046
pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Kazuki Hashiba (2017)
10.1016/S0378-5173(97)04885-0
Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters
A. J. Almeida (1997)
10.1016/S0378-5173(02)00180-1
Nanostructured lipid matrices for improved microencapsulation of drugs.
R. Mueller (2002)
10.1016/j.ijpharm.2015.12.046
Nanoparticle transport across in vitro olfactory cell monolayers.
O. Gartziandia (2016)
10.1002/9781118971147.CH20
Q8(R2): Pharmaceutical Development
P. Holm (2017)
10.1007/s00018-005-5109-0
Cell-penetrating peptides: tools for intracellular delivery of therapeutics
S. Deshayes (2005)
10.1016/j.jconrel.2012.12.013
Biocompatibility of engineered nanoparticles for drug delivery.
S. Naahidi (2013)
10.3390/molecules200713313
Cell-Penetrating Peptides: Possibilities and Challenges for Drug Delivery in Vitro and in Vivo
T. Skotland (2015)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Ahmed M. Mansour (2003)
10.1211/jpp.59.1.0010
Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification
S. Chono (2007)
10.1158/1078-0432.CCR-07-1441
Therapeutic Nanoparticles for Drug Delivery in Cancer
Kwangjae Cho (2008)
10.2147/IJN.S77837
Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA
Z. Shao (2015)
10.1002/adma.201200832
Peptide targeted lipid nanoparticles for anticancer drug delivery.
Timothy R. Pearce (2012)
10.1021/acsnano.5b02796
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles.
S. Ramishetti (2015)
10.1016/J.COLSURFB.2005.06.001
Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery.
Quan Gan (2005)
10.1080/21691401.2017.1296847
Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
Saeideh Abdolahpour (2018)
10.1016/j.colsurfb.2017.11.008
Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability.
Xuqi Kang (2018)
10.1016/j.yexmp.2008.12.004
Nanoparticle-based targeted drug delivery.
R. Singh (2009)
10.3109/08982104.2012.662653
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma
J. Varshosaz (2012)
10.1016/0378-5173(93)90177-H
Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction
K. Westesen (1993)
10.1021/mp300649z
Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
H. Yuan (2013)
10.1186/s12951-016-0177-x
Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E
A. Neves (2016)
10.1016/j.carbpol.2014.08.026
Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells.
T. H. Tran (2014)
10.1016/j.colsurfb.2016.02.029
The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles.
T. Pan (2016)
10.1007/s10544-017-0188-x
Lipid nanoparticles for administration of poorly water soluble neuroactive drugs
E. Esposito (2017)
10.1016/J.IJPHARM.2007.10.014
Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.
Jiesheng Ye (2008)
10.1016/j.molmed.2015.01.001
Cancer Nanomedicine: From Targeted Delivery to Combination Therapy
Xiaoyang Xu (2015)
10.2147/DDDT.S104395
Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis
M. Pinheiro (2016)
Novel solid lipid nanoparticles as carriers for oral administration of insulin.
Zhenhai Zhang (2009)
10.1186/s13578-015-0041-y
Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles
Arvind Thakkar (2015)
10.1146/annurev-bioeng-071812-152409
Multifunctional nanoparticles for drug delivery and molecular imaging.
G. Bao (2013)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1016/j.canlet.2012.07.002
Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
Xiao-yan Yang (2013)
10.1166/JBN.2017.2338
Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy.
chih-hung chuang (2017)
10.2174/138161209789649547
Saccharide modified pharmaceutical nanocarriers for targeted drug and gene delivery.
Wangyang Yu (2009)
10.1002/biot.201400162
Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
P. Resnier (2014)
10.1016/J.ADDR.2007.04.011
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
10.1208/s12249-010-9563-0
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
S. Das (2010)
10.1016/j.addr.2012.09.040
Historical perspective on advanced drug delivery: how engineering design and mathematical modeling helped the field mature.
N. Peppas (2013)
10.1016/j.biomaterials.2013.03.013
Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles.
Y. Kuo (2013)
10.1016/j.ejps.2011.09.017
Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis.
R. Lopes (2012)
10.1166/JBN.2007.049
Lipid nanoparticles (SLN (R), NLC (R)) for cutaneous drug delivery
E. Souto (2007)
10.1016/j.biomaterials.2010.11.063
Tumor transfection after systemic injection of DNA lipid nanocapsules.
M. Morille (2011)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
10.1007/s40005-017-0329-5
Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting
C. Kim (2017)
10.1111/j.2042-7158.2010.01225.x
Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery
S. Dhawan (2011)
10.1007/s11095-006-9662-5
Long Circulating Poly(Ethylene Glycol)-Decorated Lipid Nanocapsules Deliver Docetaxel to Solid Tumors
M. Khalid (2006)
10.1016/J.IJROBP.2003.10.057
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
L. Li (2004)
10.1016/j.colsurfb.2011.03.035
Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound.
A. Silva (2011)
10.1016/S0169-409X(02)00118-7
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
R. Mueller (2002)
10.1080/10837450.2016.1226901
Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines
Nargess Gandomi (2017)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
10.1016/j.jconrel.2008.05.009
Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives.
Huan Xu (2008)
10.1007/s11095-014-1572-3
Rifampicin Loaded Mannosylated Cationic Nanostructured Lipid Carriers for Alveolar Macrophage-specific Delivery
Xu Song (2014)
10.1002/adhm.201400675
Targeting and microenvironment-responsive lipid nanocarrier for the enhancement of tumor cell recognition and therapeutic efficiency.
W. Gao (2015)
10.2174/1385272820666161031161101
Targeted Delivery of Lipid Nanoparticles by Means of Surface Chemical Modification
D. Gaspar (2017)
10.1016/j.nucmedbio.2017.01.004
PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs.
P. Wong (2017)
10.1007/s11095-014-1469-1
Enhanced Oral Delivery of Curcumin from N-trimethyl Chitosan Surface-Modified Solid Lipid Nanoparticles: Pharmacokinetic and Brain Distribution Evaluations
P. Ramalingam (2014)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1166/JNN.2006.425
Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model.
N. Zhang (2006)
10.1166/JBT.2015.1289
Biotinylated Epidermal Growth Factor Surface Modified Lipid Nanoparticles to Enhance the Targeting Efficiency in Liver Cancer Therapy
Jian Zhang (2015)
10.1002/adhm.201200006
A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.
Adam J Shuhendler (2012)
10.1016/j.ejps.2011.09.018
Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles.
A. Cadete (2012)
10.1211/jpp.59.7.0004
Transferrin‐conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain
Yashwant Gupta (2007)
10.1016/J.EJPS.2005.02.008
A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
M. Garcia-Fuentes (2005)
10.1002/JPS.2600651217
Polymerized micelles and their use as adjuvants in immunology.
G. Birrenbach (1976)
10.1007/s11095-010-0149-z
Mannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages
Wangyang Yu (2010)
10.1016/j.addr.2009.03.009
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
P. Aggarwal (2009)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/j.jconrel.2012.12.021
Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
A. Beloqui (2013)
10.1021/mp800051m
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
F. Alexis (2008)
10.1080/1061186021000001832
Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate
C. Olbrich (2002)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1038/mt.2015.175
Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses
Joseph A. Katakowski (2016)
10.1016/j.ijpharm.2015.11.050
Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies.
D. P. Gaspar (2016)
10.1016/j.colsurfb.2012.01.001
Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
Vinay Kumar Venishetty (2012)
10.1016/j.ejpb.2014.06.011
Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs.
T. Fan (2014)
10.1007/s11095-007-9284-6
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
L. E. V. Vlerken (2007)
10.1039/c4nr01510j
A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.
Zhaogang Yang (2014)
10.1016/j.biomaterials.2009.03.009
The encapsulation of DNA molecules within biomimetic lipid nanocapsules.
A. Vonarbourg (2009)
10.1186/2045-3701-5-1
Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures
G. D. Keppeke (2014)
10.1007/s11095-014-1320-8
Targeted Paclitaxel Delivery to Tumors Using Cleavable PEG-Conjugated Solid Lipid Nanoparticles
J. Zheng (2014)
10.2217/nnm.10.107
Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances.
Joshua Buse (2010)
10.1016/j.nano.2012.03.003
Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles.
Vinay Kumar Venishetty (2013)
10.1002/EJLT.201400431
Lecithin and parabens play a crucial role in tripalmitin-based lipid nanoparticle stabilization throughout moist heat sterilization and freeze-drying
G. Mancini (2015)
10.1002/med.20171
Recent developments in carbohydrate‐decorated targeted drug/gene delivery
H. Zhang (2010)
10.1039/9781849735292-00483
Chapter 8.3. Drug Delivery Strategies: Lipid Nanocapsules
G. Bastiat (2012)
10.3109/1061186X.2010.523787
Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route
S. Patel (2011)
10.1016/j.jconrel.2016.11.016
The principles and applications of avidin‐based nanoparticles in drug delivery and diagnosis
Akshay Jain (2017)
10.1016/j.biomaterials.2009.09.044
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
M. Morille (2010)
10.1016/J.TIFS.2011.08.003
Nanoencapsulation of food ingredients using lipid based delivery systems
Milad Fathi (2012)
10.1016/j.ijpharm.2010.07.021
Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis.
Rohit S. Mulik (2010)
10.3109/1061186X.2015.1068320
Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting
I. Singh (2016)
10.1016/S0169-409X(02)00026-1
PEGylated antibodies and antibody fragments for improved therapy: a review.
A. P. Chapman (2002)
10.7150/thno.10804
Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells
Hongxin Shen (2015)
10.1088/0957-4484/26/49/495103
Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E.
A. Neves (2015)
10.3109/03639045.2014.891130
Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel
P. Sahu (2015)
10.1016/S0378-5173(02)00269-7
Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid.
Soo-Jeong Lim (2002)
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
Melike Üner (2007)
10.1016/J.TIBTECH.2007.09.005
Nanoparticles for drug delivery to the lungs.
Jean Sung (2007)
10.1155/2011/414729
Mechanisms of Cellular Uptake of Cell-Penetrating Peptides
Fatemeh Madani (2011)
10.1016/j.biomaterials.2013.09.093
Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles.
Y. Lu (2014)
10.1016/j.addr.2011.03.014
Polymeric multilayer capsules delivering biotherapeutics.
S. de koker (2011)
10.2147/IJN.S34991
Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine
Yan Chen (2012)
10.1007/s13346-011-0023-5
Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin
P. Fonte (2011)
10.1016/j.actbio.2016.04.026
Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Indranil Banerjee (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar